PIVOT IO 009: A Phase 3, Randomized Study of Neoadjuvant and Adjuvant Nivolumab (NIVO) Plus Bempegaldesleukin (BEMPEG; NKTR-214) Versus NIVO Alone Versus Standard of Care (SOC) in Patients (pts) with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin (Cis)-Ineligible.
Journal of Clinical Oncology（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined